Kirkland & Ellis LLP advised AbbVie Inc. (NYSE: ABBV), a global, research-driven biopharmaceutical company, on its agreement to acquire Allergan plc (NYSE: AGN), a global pharmaceutical leader, in a cash and stock transaction for an equity value of approximately $63 billion. The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology. The transaction is subject to regulatory approvals and is expected to close in early 2020.
PRESS RELEASE
4 July 2019
Kirkland Represents AbbVie On Acquisition Of Allergan For $63 Billion
Kirkland & Ellis International LLP
Contributor
Kirkland & Ellis LLP advised AbbVie Inc. (NYSE: ABBV), a global, research-driven biopharmaceutical company, on its agreement to acquire Allergan plc (NYSE: AGN),